| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Guanidino-G-Clamp-PNA (4 μM cGPNA2; 48 h) inhibited miR-155, upregulated its downstream tumor suppressor gene targets, and downregulated the expression of oncogenes in U2932 diffuse large B-cell lymphoma cells [1]. Guanidino-G-Clamp-PNA (4 μM cGPNA2; 48 h) potently inhibited miR-155 and regulated the expression of downstream tumor suppressor genes and oncogenes in SUDHL-5 diffuse large B-cell lymphoma cells [1]. Guanidino-G-Clamp-PNA (1-4 μM cGPNA5; 24 h) reduced the level of TTR mRNA in HepG2 cells in vitro in a dose-dependent manner. After treatment with 4 μM for 24 hours, the knockdown rate of TTR mRNA reached 69% [1]. Guanidino-G-Clamp-PNA (0.5–4 μM cGPNA2; 48 h) reduced the viability of U2932 and SUDHL-5 diffuse large B-cell lymphoma cells and induced apoptosis in a dose-dependent manner; after 48 hours of treatment with 4 μM, cell viability decreased by ≥60%, and the proportion of late apoptotic cells in U2932 cells was approximately 20% [1]. Guanidino-G-Clamp-PNA (2–4 μM cGPNA5; 3 h) inhibited the translation of TTR mRNA in a cell-free system of rabbit reticulocyte lysate. After pre-incubation at 37°C with a 1:4 ratio of mRNA to reagent for 3 hours, TTR protein levels decreased by 62% [1].
|
|---|---|
| Cell Assay |
RT-PCR[1]
Cell Types: HepG2 hepatocellular carcinoma cells Tested Concentrations: 1-4 μM cGPNA5 Incubation Duration: 24 hours Experimental Results: The level of TTR mRNA induced decreased in a dose-dependent manner, and decreased by 69% at 4 μM compared with the control PNA. Cell viability assay [1] Cell Types: U2932 and SUDHL-5 diffuse large B-cell lymphoma cells Tested Concentrations: 0.5-4 μM cGPNA2 Incubation Duration: 48 hours Experimental Results: cGPNA2 dose-dependently reduced cell viability by ≥60% at a concentration of 4 μM. It dose-dependently increased the luminescence intensity of dead cells. At a concentration of 4 μM, it induced approximately 20% of late apoptotic cells, significantly higher than the unmodified PNA and PBS control groups. It dose-dependently increased the luminescence intensity of dead cells. |
| References |
| Molecular Formula |
C50H46N8O12
|
|---|---|
| Molecular Weight |
950.95
|
| CAS # |
476667-31-9
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0516 mL | 5.2579 mL | 10.5158 mL | |
| 5 mM | 0.2103 mL | 1.0516 mL | 2.1032 mL | |
| 10 mM | 0.1052 mL | 0.5258 mL | 1.0516 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
